Literature DB >> 33546453

The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer.

Fong-Yu Cheng1, Chia-Hsin Chan2, Bour-Jr Wang3,4, Ya-Ling Yeh5, Ying-Jan Wang5,6,7, Hui-Wen Chiu7,8,9,10.   

Abstract

Cancer response to chemotherapy is regulated not only by intrinsic sensitivity of cancer cells but also by tumor microenvironment. Tumor hypoxia, a condition of low oxygen level in solid tumors, is known to increase the resistance of cancer cells to chemotherapy. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Due to lack of target in TNBC, chemotherapy is the only approved systemic treatment. We evaluated the effect of hypoxia on chemotherapy resistance in TNBC in a series of in vitro and in vivo experiments. Furthermore, we synthesized the calcium peroxide-modified magnetic nanoparticles (CaO2-MNPs) with the function of oxygen generation to improve and enhance the therapeutic efficiency of doxorubicin treatment in the hypoxia microenvironment of TNBC. The results of gene set enrichment analysis (GSEA) software showed that the hypoxia and autophagy gene sets are significantly enriched in TNBC patients. We found that the chemical hypoxia stabilized the expression of hypoxia-inducible factor 1α (HIF-1α) protein and increased doxorubicin resistance in TNBC cells. Moreover, hypoxia inhibited the induction of apoptosis and autophagy by doxorubicin. In addition, CaO2-MNPs promoted ubiquitination and protein degradation of HIF-1α. Furthermore, CaO2-MNPs inhibited autophagy and induced apoptosis in TNBC cells. Our animal studies with an orthotopic mouse model showed that CaO2-MNPs in combination with doxorubicin exhibited a stronger tumor-suppressive effect on TNBC, compared to the doxorubicin treatment alone. Our findings suggest that combined with CaO2-MNPs and doxorubicin attenuates HIF-1α expression to improve the efficiency of chemotherapy in TNBC.

Entities:  

Keywords:  autophagy; chemoresistance; hypoxia; nanocarriers; triple-negative breast cancer

Year:  2021        PMID: 33546453      PMCID: PMC7913619          DOI: 10.3390/cancers13040606

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  47 in total

1.  Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.

Authors:  Shuang Qiu; Liang Sun; Ye Jin; Qi An; Changjiang Weng; Jianhua Zheng
Journal:  Oncol Rep       Date:  2017-06-06       Impact factor: 3.906

2.  Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer.

Authors:  Fengqiao Li; Hao Mei; Yu Gao; Xiaodong Xie; Huifang Nie; Tao Li; Huijuan Zhang; Lee Jia
Journal:  Biomaterials       Date:  2017-08-18       Impact factor: 12.479

Review 3.  Ubiquitin, proteasomes, and the regulation of intracellular protein degradation.

Authors:  M Hochstrasser
Journal:  Curr Opin Cell Biol       Date:  1995-04       Impact factor: 8.382

4.  Oxygen release kinetics from solid phase oxygen in Arctic Alaska.

Authors:  T Schmidtke; D White; C Woolard
Journal:  J Hazard Mater       Date:  1999-01-29       Impact factor: 10.588

5.  Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells.

Authors:  George P Tuszynski; Meena R Sharma; Vicki L Rothman; Mahesh C Sharma
Journal:  Microvasc Res       Date:  2002-11       Impact factor: 3.514

Review 6.  Nanotechnological carriers for cancer chemotherapy: the state of the art.

Authors:  Marilene Estanqueiro; Maria Helena Amaral; Jaime Conceição; José Manuel Sousa Lobo
Journal:  Colloids Surf B Biointerfaces       Date:  2015-01-03       Impact factor: 5.268

7.  c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia.

Authors:  Katrina M Comerford; Eoin P Cummins; Cormac T Taylor
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

8.  Hypoxia-regulated gene network in drug resistance and cancer progression.

Authors:  Shao-Chieh Lin; Wan-Lin Liao; Jenq-Chang Lee; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2014-05-08

9.  A biomimetic 3D model of hypoxia-driven cancer progression.

Authors:  Chiara Liverani; Alessandro De Vita; Silvia Minardi; Yibin Kang; Laura Mercatali; Dino Amadori; Alberto Bongiovanni; Federico La Manna; Toni Ibrahim; Ennio Tasciotti
Journal:  Sci Rep       Date:  2019-08-22       Impact factor: 4.379

10.  Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.

Authors:  Michelle Cicchini; Rumela Chakrabarti; Sameera Kongara; Sandy Price; Ritu Nahar; Fred Lozy; Hua Zhong; Alexei Vazquez; Yibin Kang; Vassiliki Karantza
Journal:  Autophagy       Date:  2014-10-30       Impact factor: 16.016

View more
  1 in total

Review 1.  Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Nikita Jinna; Padmashree Rida; Max Smart; Mark LaBarge; Tijana Jovanovic-Talisman; Rama Natarajan; Victoria Seewaldt
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.